Chimeric Infectious Bursal Disease Virus-Like Particles as Potent Vaccines for Eradication of Established HPV-16 E7–Dependent Tumors
Figure 2
Immunization with VLP-E7 elicits E7 peptide–directed IFN- γ –secreting splenocytes.
A) IFN- γ –secreting splenocytes from mice (n = 5) immunized twice with either 50 µg of VLP-E7 or VLP-WT or PBS, with or without Sigma Adjuvant System (SAS), were quantified ex vivo by ELISPOT assay. The splenocytes were pooled from each group of mice, plated, and either not stimulated (no peptide) or stimulated with control peptide (11–20) or with two E7 peptides (49–57, H2b epitope and 86–93 HLA-A2 epitope). Bars represent mean ± s.e.m. of six replicates. *p<0.05 compared with VLP-WT. B) IFN- γ –secreting splenocytes from mice (n = 5) immunized twice with either 50 µg of VLP-WT or 50 µg of VLP-E7 alone or with adjuvants (50 µg CpGs or 50 µg Poly-R) were quantified by ELISPOT assay. The splenocytes were pooled from each group of mice, plated, and stimulated as in A. The background values (no peptide and peptide control wells) were subtracted from those stimulated with the 49–57 and 86–93 E7 peptides. Bars represent mean ± s.e.m. of six replicates.